Within the Chronic Inflammatory Demyelinating Polyneuropathy Market segment, the treatment landscape is primarily categorized into Intravenous Immunoglobulin (IVIg), Corticosteroids, Immunosuppressive Therapy, and Plasmapheresis. IVIg currently represents the largest revenue-generating sub-segment due to its established efficacy as a first-line treatment and the need for frequent, high-dose administration.

By Diagnosis Type, the Chronic Inflammatory Demyelinating Polyneuropathy Market segment is driven by Nerve Conduction Studies, which remain the gold standard for confirming the demyelinating nature of the polyneuropathy. However, Electromyography is emerging as a fast-growing diagnostic tool, alongside Lumbar Puncture (cerebrospinal fluid analysis), as clinicians seek more precise diagnostic confirmation and prognostic markers to guide therapeutic choices.